Treatment at discharge after myocardial infarction in 2,102 patients. The PRIMA study

Acta Cardiologica

Volumn 56, Issue 1, 2001, Pages 17-26

  Excoffier, S ^a   De Gevigney, G ^a   Ecochard, R ^a   Rabilloud, M ^a   Cao, D ^a   Cheneau, E ^a   Milon, H ^a   Delahaye, F ^a  

^a LOUIS PRADEL HOSPITAL   (France)

Author keywords

Myocardial infarction; Treatments

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NITRATE;

ADULT; AGED; ARTICLE; DIABETES MELLITUS; DRUG CHOICE; DRUG USE; FEMALE; FRANCE; HEART INFARCTION; HOSPITAL DISCHARGE; HUMAN; HYPERTENSION; KIDNEY FAILURE; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PROSPECTIVE STUDY;

EID: 0035066223     PISSN: 00015385     EISSN: None     Source Type: Journal    
DOI: 10.2143/AC.56.1.2005589     Document Type: Article

References (40)

1. Adjunctive drug therapy of acute myocardial infarction. Evidence from clinical trials
2. ACC/AHA guidelines for the management of patients with acute myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction)
3. Acute myocardial infarction: Pre-hospital and in-hospital management
4. The impact of clinical trials on the use of medications for acute myocardial infarction. Results of a community-based study
5. Do the results of randomized clinical trials of cardiovascular drugs influence medical practice?
6. Trends in the use of drug therapies in patients with acute myocardial infarction: 1988 to 1992
7. La prescription médicamenteuse dans le postinfarctus: Résultats de l'EPPI (étude de prescription postinfarctus). Etude coopérative française
8. La prescription médicamenteuse dans le postinfarctus: Résultats de l'EPPI II (étude de prescription postinfarctus). Etude coopérative française
9. Beta-blocker therapy in acute myocardial infarction: Evidence for underutilization in the elderly
10. Treatment with beta-adrenergic blocking agents after myocardial infarction: From randomized trials to clinical practice
11. Comparison of risk and patterns of practice in patients older and younger than 70 years with acute myocardial infarction in a two-year period (1987-1989)
12. Outlook after acute myocardial infarction in the very elderly compared with that in patients aged 65 to 75 years
13. Is age an independent predictor of early and late mortality in patients with acute myocardial infarction?
14. Adverse outcomes of underuse of beta-blockers in elderly survivors of acute myocardial infarction
15. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients
16. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials
17. The effect of diltiazem on mortality and reinfarction after myocardial infarction
18. Recombinant tissue-type plasminogen activator and immediate angioplasty in acute myocardial infarction. One-year follow-up
19. Secondary prevention after high-risk acute myocardial infarction with low-dose acebutolol
20. The Beta-Blocker Pooling Project (BBPP): Subgroup findings from randomized trials in post infarction patients
21. Diabetic patients and beta-blockers after acute myocardial infarction
22. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease: A meta-analysis of randomized controlled trials
23. Peripheral vascular effects of beta-blockers
24. A randomized trial of propranolol in patients with acute myocardial infarction. I. Mortality results
25. Timolol-induced reduction in mortality reinfarction in patients surviving acute myocardial infarction
26. Long-term treatment with metoprolol after myocardial infarction: Effect on 3 year mortality and morbidity
27. Controversies surrounding the use of beta-blockers in older patients with cardiovascular disease
28. Quality of life in cardiovascular diseases. Emphasis on beta-blocker treatment
29. The truth about betablocker adverse effects-depression, claudication and lipids
30. Beta-blockers, dyslipidemia, and coronary artery disease. A reassessment
31. ISIS-4: A randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction
32. GISSI-3: Effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction
33. Diltiazem and reinfarction in patients with non-Q-wave myocardial infarction. Results of a double-blind, randomized, multicenter trial
34. Effect of verapamil on mortality and major events after acute myocardial infarction (the Danish Verapamil Infarction Trial II - DAVIT II)
35. Oral captopril versus placebo among 13 634 patients with suspected acute myocardial infarction: Interim report from the Chinese Cardiac Study (CCS-1)
36. A clinical trial of the angiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction
37. Collaborative overview of randomised trials of antiplatelet therapy. I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
38. Oral anticoagulant in patients surviving myocardial infarction: A new approach to old data
39. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2